Systematic Review of the Safety and Tolerability of Injectable Prolonged-Release Buprenorphine (Buvidal) in Adults With Opioid Dependence

Aims Widely available opioid substitute treatments have numerous limitations including the potential for non-compliance, misuse, diversion and accidental overdose. The advent of a prolonged-release, injectable form buprenorphine may be solution to overcoming these issues, as well reducing intrusion on patient's daily life. Initial trials shown success in achieving significantly higher percentage abstinence compared placebo. This systematic review meta-analysis will examine efficacy, safety tolerability data. Methods A meta-analysis, all randomised controlled reporting raw data side effects buprenorphine. Included articles were identified using PubMed, Ovid (EMBASE MEDLINE), Google Scholar Cochrane Library. Participants either community outpatients or hospital inpatients, aged over 18 years, with use disorder. Interventions prolonged-release injectablebuprenorphine any preparation dosing schedule, control such sublingual primary outcome measure was treatment specifically retention negative urine drug screen results. secondary outcomes measures related adverse events, severe nonfatal serious mortality, discontinuation, Six selected inclusion following assessment our exclusion criteria. Study quality assessed CASP tool Risk Bias 2. Review Manager 5.4.1 used synthesis. Results Our endpoint samples surrogate markers. Regarding there statistically significant increase ‘Buvidal’ group (OR = 1.46, 95% CI 1.12 1.89, P 0.005). There also 1.38, 1.26 1.52, < 0.00001). We examined number which focussed These showed no differences between two groups (drug overdose 0.09), events 1.75), 0.93), 0.65), mortality 1.63) discontinuation 1.52)). Conclusion studies efficacy comparison groups, difference their effect profiles. To knowledge, this is first its kind, results support hypothesis that an effective safe